Liraglutide in the treatment of obesity

Expert Opinion on Biological Therapy

Volumn 14, Issue 8, 2014, Pages 1215-1224

  Ng, Sarah Yoon Ai ^a   Wilding, John P H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Glucagon like peptide 1 receptor agonist; Liraglutide; Obesity; Overweight

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIRAGLUTIDE; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; LACTONE;

ACUTE PANCREATITIS; APPETITE; BLOOD PRESSURE REGULATION; CALORIC INTAKE; CHOLELITHIASIS; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INJECTION SITE BLEEDING; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INSULIN RELEASE; MORBIDITY; MORTALITY; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; TREATMENT OUTCOME;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LACTONES; OBESITY; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84904001116     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.925870     Document Type: Review

References (49)

1. Sassi F. Obesity and the economics of prevention: Fit not fat. OECD Publishing; 2010
2. Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378(9793):815-25
3. Pi-Sunyer FX. Why drugs? In: Wilding JH, editor. Pharmacotherapy of obesity. Birkhauser: Basel; 2008. p. 1-10
4. Borgstrom B. Mode of action of tetrahydrolipstatin: A derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988;962(3):308-16
5. LeBlanc E, O'Connor E, Whitlock EP, et al. Screening for and management of obesity and overweight in adults. Agency for Healthcare Research and Quality; Rockville, MD: 2011
6. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002;56(7):494-9
7. Torgerson JS, Hauptman J, Boldrin MN, Sjeostreom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61 (Pubitemid 38196725)
8. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59(2):151-84 (Pubitemid 46855438)
9. Fleming JW, McClendon KS, Riche DM. New obesity agents: Lorcaserin and phentermine/topiramate. Ann Pharmacother 2013;47(7-8):1007-16
10. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
11. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16(4):354-64
12. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308
13. Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann NY Acad Sci 2014;1311:1-13
14. Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: A systematic review and meta-Analysis. Obes Surg 2014;24(3):437-55
15. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20(6):876-913 (Pubitemid 30647076)
16. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101(3):515-20 (Pubitemid 28084232)
17. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23(3):304-11 (Pubitemid 29118862)
18. Gutzwiller JP, Geoke B, Drewe J, et al. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999;44(1):81-6 (Pubitemid 29143284)
19. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379(6560):69-72 (Pubitemid 26008136)
20. Shirazi R, Palsdottir V, Collander J, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci USA 2013;110(40):16199-204
21. Information about Liraglutide. Available from: Http://www.novonordisk. com/ science/pipeline/liraglutide.asp
22. Agerso H, Jensen LB, Elbrønd B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-Acting GLP-1 derivative, in healthy men. Diabetologia 2002;45(2):195-202 (Pubitemid 34208381)
23. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84(10):3434-8 (Pubitemid 17085418)
24. Perfetti R, Merkel P. Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000;143(6):717-25 (Pubitemid 32066697)
25. Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci 2013;102(8):2882-8
26. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999;140(11):5356-63
27. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-Acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-404 (Pubitemid 41071152)
28. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38(11):1944-53
29. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-The FDAs review of a new antidiabetic therapy. N Engl J Med 2010;362(9):774-7
30. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-86
31. Astrup A, Reossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
32. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36(6):843-54
33. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37(11):1443-51
34. Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014;38(5):689-97
35. Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med 2012;12(5):456-60
36. Levine HJ. Resting heart rate and life expectancy. J Am Coll Cardiol 1997;30(4):1104-6 (Pubitemid 27435908)
37. Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996;78(10):1175-6 (Pubitemid 126657187)
38. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: The Ohasama study. Am J Hypertens 2004;17(11 Pt 1):1005-10 (Pubitemid 39469321)
39. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and metaanalysis. BMJ Open 2013;3:e001986, doi:10.1136/bmjopen-2012-001986
40. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8(3):237-40
41. Alves C, BATEL-MARQUES F, MACEDO AF A meta-Analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98(2):271-84
42. A.2011. Available from: Http://www.fda. gov/safety/medwatch/ safetyinformation/ safetyalertsforhumanmedicalproducts/ ucm258826.htm
43. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care 2009;32(5):834-8
44. Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg Clin North Am 2008;88(6):1175-94.vii
45. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96(3):853-60
46. Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating second-line treatment options for type 2 diabetes: Focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Ann Pharmacother 2013;47(4):490-505
47. Liraglutide for the treatment of type 2 diabetes mellitus. National Institute of Health and Clinical Excellence (NICE); 2010. Available from: Http://www.nice.org.uk/ nicemedia/live/13248/51259/51259.pdf
48. Tucker ME. Diabetes drug eyed as obesity treatment 2014. Available from: Http://www.medscape. com/viewarticle/825697?src=rss
49. World Health Organisation. Obesity and overweight. Available from: Http://www. who.int/mediacentre/factsheets/fs311/en/.